Thomas Smith
Stock Analyst
(1.59)
# 1,507
Out of 4,648 analysts
68
Total ratings
41.3%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Outperform | $29 | $11.42 | +153.94% | 1 | Jul 23, 2024 | |
| QTTB Q32 Bio | Initiates: Outperform | $54 | $46.84 | +15.29% | 1 | May 21, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $19.11 | +104.08% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $5.42 | +379.70% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $2.27 | +340.53% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $10.55 | +89.57% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $588.67 | -26.10% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $58.25 | -38.20% | 1 | Feb 28, 2023 | |
| EQ Equillium | Maintains: Outperform | $12 → $7 | $0.75 | +833.21% | 3 | Feb 8, 2023 | |
| CNTB Connect Biopharma Holdings | Maintains: Outperform | $9 → $7 | $1.20 | +483.33% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $29.42 | -28.62% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $22.84 | +97.02% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $3.04 | +97.37% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $7.09 | -15.37% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.20 | +316.67% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $46.40 | -63.36% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $25.39 | +152.07% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $20.83 | +236.05% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $9.29 | +212.16% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $4.83 | +438.30% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $1.25 | +860.00% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $63.14 | -80.99% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $5.76 | +73.61% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $6.73 | +5,843.54% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $26 | $2.17 | +1,098.16% | 6 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $59.95 | +33.44% | 2 | Dec 8, 2020 |
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $11.42
Upside: +153.94%
Q32 Bio
May 21, 2024
Initiates: Outperform
Price Target: $54
Current: $46.84
Upside: +15.29%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $19.11
Upside: +104.08%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $5.42
Upside: +379.70%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $2.27
Upside: +340.53%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $10.55
Upside: +89.57%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $588.67
Upside: -26.10%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $58.25
Upside: -38.20%
Equillium
Feb 8, 2023
Maintains: Outperform
Price Target: $12 → $7
Current: $0.75
Upside: +833.21%
Connect Biopharma Holdings
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.20
Upside: +483.33%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $29.42
Upside: -28.62%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $22.84
Upside: +97.02%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $3.04
Upside: +97.37%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $7.09
Upside: -15.37%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.20
Upside: +316.67%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $46.40
Upside: -63.36%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $25.39
Upside: +152.07%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $20.83
Upside: +236.05%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $9.29
Upside: +212.16%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $4.83
Upside: +438.30%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $1.25
Upside: +860.00%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $63.14
Upside: -80.99%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $5.76
Upside: +73.61%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $6.73
Upside: +5,843.54%
Mar 4, 2021
Maintains: Outperform
Price Target: $21 → $26
Current: $2.17
Upside: +1,098.16%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $59.95
Upside: +33.44%